E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Influence of CYP2D6 polymorphism on metoprolol pharmacokinetics and pharmacodynamics in human volunteers |
|
E.1.1.1 | Medical condition in easily understood language |
A class-room experiment to investigate the genetic differences regarding effects of metoprolol in human volunteers |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Metabolic Phenomena [G03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10007521 |
E.1.2 | Term | Cardiac arrhythmias |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10015488 |
E.1.2 | Term | Essential hypertension |
E.1.2 | System Organ Class | 10047065 - Vascular disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To educate students about the full life cycle of clinical trials including study set-up, design, execution, analysis and reporting To explore the influence of CYP2D6 polymorphism on the pharmacodynamics and pharmacokinetics of metoprolol in healthy volunteers
|
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Signed informed consent and willing to comply with the study restrictions • Healthy male or female subjects aged between 18 and 40 years • Non-smoking, with no clinically relevant abnormalities • Agree to abstain from caffeine (including coffee, tea, chocolate, or caffeine-containing soft drinks) intake from 24 hours prior to the first dose until the end of the study • The subject is willing and able to abstain from grapefruit, grapefruit juice or any other grapefruit-containing products for 72 hours prior to the first dose of study drug until the end of the study • Body weight greater than or equal to 45 kilogram (kg) at screening • Be able to refrain from strenuous physical exercise from 48 hours prior to each dosing period. • No significant ECG abnormalities.
|
|
E.4 | Principal exclusion criteria |
• Concomitant clinical significant diseases at baseline, e.g., known cardiovascular or pulmonary disease, renal or liver dysfunction, ECG or laboratory abnormalities, etc. • Resting heart rate less than 45 bpm and blood pressure less than 105/60 millimeter of mercury (mmHg) • Have a known or suspected intolerance or hypersensitivity to any biologic medication or known allergies or clinically significant reactions to murine, chimeric, or human peptides or proteins • Pregnancy or childbearing potential without adequate contraception • Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year • No blood donating or blood loss within 60 days prior to screening or plasma donating within 7 days prior screening.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Vital signs (pulse rate in bpm, systolic and diastolic blood pressure in mmHg, electrocardiogram), plasma concentration of metoprolol |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At baseline, 0.5, 1, 1.5, 2, 3, 4, 5 and 6 hours after administration |
|
E.5.2 | Secondary end point(s) |
Efficacy of metoprolol compared to placebo, measured in vital signs (pulse rate, blood pressure and ECG) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At baseline, 0.5, 1, 1.5, 2, 3, 4, 5 and 6 hours after administration |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 6 |